Evidence map›Paper›PMID 25698928›Full record

ArticleFrontiers in cellular neuroscience2015

Systems biology analysis of the proteomic alterations induced by MPP(+), a Parkinson's disease-related mitochondrial toxin.

Chiara Monti, Heather Bondi, Andrea Urbani, Mauro Fasano, Tiziana Alberio

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Neuroprotective Effects of Huperzine B andAdvances in pharmacological and pharmaceutical sciences · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. The delta-opioid receptor and Parkinson's disease.CNS neuroscience & therapeutics · 2018
    Review
  8. GSK-3β Inhibitor Alsterpaullone Attenuates MPPFrontiers in cellular neuroscience · 2018
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chiara MontiBiomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria Busto Arsizio, Italy.
Heather BondiBiomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria Busto Arsizio, Italy ; Center of Neuroscience, University of Insubria Busto Arsizio, Italy.
Andrea UrbaniSanta Lucia IRCCS Foundation Rome, Italy ; Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata," Rome, Italy.
Mauro FasanoBiomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria Busto Arsizio, Italy ; Center of Neuroscience, University of Insubria Busto Arsizio, Italy.
Tiziana AlberioBiomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria Busto Arsizio, Italy ; Center of Neuroscience, University of Insubria Busto Arsizio, Italy.
University of Insubria · ITFondazione Santa Lucia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disease whose etiology has not been completely characterized. Many cellular processes have been proposed to play a role in the neuronal damage and loss: defects in the proteosomal activity, altered protein processing, increased reactive oxygen species burden. Among them, the involvement of a decreased activity and an altered disposal of mitochondria is becoming more and more evident. The mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)), an inhibitor of complex I, has been widely used to reproduce biochemical alterations linked to PD in vitro and its precursor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP), to induce a Parkinson-like syndrome in vivo. Therefore, we performed a meta-analysis of the literature of all the proteomic investigations of neuronal alterations due to MPP(+) treatment and compared it with our results obtained with a mitochondrial proteomic analysis of SH-SY5Y cells treated with MPP(+). By using open-source bioinformatics tools, we identified the biochemical pathways and the molecular functions mostly affected by MPP(+), i.e., ATP production, the mitochondrial unfolded stress response, apoptosis, autophagy, and, most importantly, the synapse funcionality. Eventually, we generated protein networks, based on physical or functional interactions, to highlight the relationships among the molecular actors involved. In particular, we identified the mitochondrial protein HSP60 as the central hub in the protein-protein interaction network. As a whole, this analysis clarified the cellular responses to MPP(+), the specific mitochondrial proteome alterations induced and how this toxic model can recapitulate some pathogenetic events of PD.

Indexed as

meta-analysisMPP+network enrichmentover-representation analysissystems biology

Identifiers

PMID25698928
PMCPMC4313704
OpenAlexW2036777245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.